PTC Therapeutics (PTCT) PT Raised to $70 at Citi, 'Post-data, we increased our sepiapterin POS to 90%'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. CVS
9. SPY
10. XYZ

Go back to PTC Therapeutics (PTCT) PT Raised to $70 at Citi, 'Post-data, we increased our sepiapterin POS to 90%'

PTC Therapeutics (PTCT) PT Raised to $37 at Goldman Sachs, 'stock in an increasingly precarious position ahead of higher risk'

May 17, 2023 2:39 PM EDT

(Updated - May 17, 2023 2:40 PM EDT)

Goldman Sachs analyst Paul Choi raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $37.00 (from $35.00) while maintaining a Sell rating.

The analyst comments "

Sepiapterin shows consistent efficacy and clean safety; MOVE-FA data later in May the next key catalyst. PTCT shares are trading up to a 52-week high (+42% YTD... More

PTC Therapeutics (PTCT) Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients

May 17, 2023 7:02 AM EDT

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the primary endpoint was achieved in the APHENITY, Phase 3 registration-directed clinical trial of sepiapterin in adult and pediatric patients with phenylketonuria (PKU).

"The positive results from the APHENITY trial bring us one step... More